Clairity has received FDA de novo authorization for Clarity Breast, an AI tool that predicts five-year breast cancer risk from screening mammograms.
Key Details
- 1Clairity Breast predicts future breast cancer risk using AI analysis of 2D screening mammograms.
- 2FDA de novo authorization has been granted for the software platform.
- 3The AI model was trained on 450,000+ mammograms and validated on 77,000 exams with five-year follow-up data.
- 4Unlike CAD tools, the software provides a risk percentage for patients rather than assisting real-time interpretation.
- 5Models were developed for diverse populations, addressing historic limitations in risk prediction for non-European ancestry.
- 6Currently available for Hologic mammography systems, with future plans for multivendor and 3D support.
Why It Matters
This represents a significant advance in leveraging mammogram images beyond immediate diagnosis, opening new avenues for personalized risk assessment in breast imaging. The FDA clearance and focus on diversity in model training mark meaningful steps toward broader clinical adoption and equity.
Source
AuntMinnie
Related News
•Radiology Business
RadNet Acquires AI Firm Gleamer in $270M Deal to Expand Radiology Solutions
RadNet will acquire Gleamer for up to $270 million, aiming to make DeepHealth the largest global provider of radiology clinical AI solutions.
•Radiology Business
Harrison.ai Petitions FDA for CAD Device Premarket Review Exemption
Harrison.ai has petitioned the FDA to exempt some radiology AI devices from premarket review, prompting mixed feedback from industry stakeholders.
•Radiology Business
Real-World Study: AI Improves Breast Cancer Detection in 3D Mammography
AI use in breast radiology increased cancer detection without higher recall rates, according to a 100,000+ case multicenter study.